TG Therapeutics' BRIUMVI Trial Data Shows Significant MS Relapse Reduction

Edgen Stock·Mar 09 2026, 12:03

Share to

Share to

Copy link

Key Takeaways

TG Therapeutics published a new analysis from its Phase 3 trials for BRIUMVI, demonstrating superior efficacy in treating highly active relapsing multiple sclerosis (MS). The data, published in a peer-reviewed journal, shows the drug significantly reduces relapse rates and MRI activity compared to a key competitor, potentially strengthening its market position.

Superior Efficacy: BRIUMVI showed statistically significant reductions in MS relapse rates and MRI activity compared to the drug teriflunomide.
Targeted Patient Group: The positive results were observed in a high-need population of patients with highly active relapsing MS.
Peer-Reviewed Validation: The findings were published in the medical journal Neurology and Therapy, adding clinical credibility to BRIUMVI's profile.

BRIUMVI Shows Superior Efficacy in High-Activity MS

TG Therapeutics announced on March 9, 2026, the publication of new data reinforcing the efficacy of its multiple sclerosis (MS) drug, BRIUMVI®. The analysis, published in the peer-reviewed journal Neurology and Therapy, pooled results from the Phase 3 ULTIMATE I and II studies. It focused specifically on patients with highly active relapsing MS, defined as those having two or more relapses in the prior year and at least one gadolinium-enhancing (Gd+) brain lesion at baseline.

Data Reinforces Competitive Edge Over Teriflunomide

The analysis demonstrated that BRIUMVI achieved statistically significant reductions in both relapse rates and MRI-detected disease activity when compared directly to the established treatment, teriflunomide. Patients treated with BRIUMVI also showed significantly higher rates of achieving "no evidence of disease activity" (NEDA-3). This strong clinical evidence positions BRIUMVI favorably against competitors, potentially leading to increased prescription rates and a stronger market share within the MS treatment sector.